Average Number of Treatments
|Standard Radiation||CyberKnife M6|
Treatment at Gibbs Cancer Center & Research Institute at Pelham gives you access to the latest advancement in CyberKnife technology with the recent introduction of a second generation multi-leaf colmnater. A state-of-the-art upgrade that, when combined with the CyberKnife’s advanced robotic targeting, has cut prostate cancer treatment times in half, while reducing radiation to other vital organs.
Additionally, Gibbs Cancer Center & Research Institute at Pelham is one of the first in the U.S. to use SpaceOAR®, the first FDA-approved method for placing a “spacer” that moves the prostate away from the rectum. This allows delivery of radiation to the prostate while providing additional protection of the rectal area. The CyberKnife/SpaceOAR combination at Gibbs results in fewer visits, shorter treatment times and fewer side effects.
For more information about CyberKnife, please consult with your doctor or call 1-855-DNA-GIBBS.
CyberKnife candidates include most low-risk and favorable intermediate-risk prostate cancer patients. Prostate size is not an issue.
Effectiveness of CyberKnife therapy for prostate cancer has proven to be similar to other treatment outcomes at five years. Potential issues, such as bladder incontinence, have been greatly reduced with use of CyberKnife when compared to surgery or other invasive treatments. Your follow-up visits with the radiation oncologist and your primary care doctor or urologist will include monitoring serum prostate specific antigen (PSA) levels — the best measure of disease control. PSA levels may change, but over time, you can anticipate levels will decrease – an indication that the tumor was destroyed.